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1. Abstract 
 
Adipose tissue is a loose connective tissue composed mainly of adipocytes which 
serves primarily as an energy reservoir. It also acts as an endocrine organ releasing 
hormones like adinopectin, leptin, resistin and estrogen. It also secretes inflammatory 
cytokine called adipokines which play a role in obesity related diseases1,2.  Fat cells 
have an important functional role in sustaining triglyceride, free fatty acid levels and 
insulin resistance.  
There is a big range of body fat distribution in both lean and obese adults. When body 
fat is mainly localised in the upper thoracic area from the waist, this can be defined as 
visceral whereas peripheral fat is more focused from the hips down to the legs. 
Abdominal fat is more susceptible to insulin resistance thus explaining why central 
obesity is marker of impaired glucose tolerance and is an independent risk factor for 
cardiovascular disease3 like increased risk for dyslipidaemia, hypertension, type 2 
diabetes, sleep apnoea, etc. It is also recognised that increasing amounts of peripheral 
body fat are independently associated with a reduced risk of metabolic complications4. 
Major factors that affect body fat distribution include genetic factors, alcohol intake5, 
cigarette smoking6, and the timing of onset of childhood obesity7.  
Obesity prevalence has increased worldwide with almost 50% of pregnant women are 
either overweight or obese in Australia8,9. This has considerable effects on maternal 
health with increased risk of gestational diabetes, hypertensive disorders of pregnancy 
and increased risk of obstetric intervention10,11.  Moreover, adverse neonatal 
complications were observed like birth defects, hypoglycaemia, lower Apgar scores, 
preterm delivery, neonatal intensive care unit admission and large for gestational age 
(LGA)12,13. Furthermore, these offspring are more predisposed to childhood and 
adulthood obesity, along with its associated sequelae including metabolic and 
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cardiovascular disease states14-18. Indeed, there is growing consensus that intrauterine 
growth disturbance affects fetal growth programming and development with lifelong 
effects, although the mechanisms remain to be elucidated.17-19 
Adiposity of offspring is affected by maternal body composition prior and during 
pregnancy which predisposes to lifetime obesity.20-21 Recent evidence suggests direct 
measurement of maternal abdominal subcutaneous fat thickness (SFT) negatively 
affects fetal fat composition and fetal obstetric outcomes12, 22-23. Measurement of the 
abdominal fat has been studied extensively in the general population since 1990s 
because of increased prevalence of obesity. This was replicated by researchers in the 
pregnant population in recent years. Lopes described assessment of maternal visceral 
adiposity during routine ultrasonographic examination as previously described by 
Ribeiro-Filho et al in 2003. 24 This group found a strong correlation between maternal 
visceral adiposity and fetal biometry during the second trimester.  
Body mass index (BMI) has been traditionally used to quantify amount of muscle, fat, 
and bone in an individual. Categorically classified as underweight, normal weight, 
overweight, or obese based on the value. This was calculated as weight in kilograms 
divided by the square of height in meters expressed in units of kg/m2.  The present 
study aims to determine the effect of BMI and maternal central adiposity on fetal fat 
during the second and third trimester, whether the obesogenic environment in 
pregnancy correlates with fetal fat accumulation in utero.  
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2. Literature review 
2.1. Obesity in Pregnancy 
2.1.1. Introduction 
The prevalence of maternal obesity has increased and continues to rise in both well-
resourced countries and lesser resourced countries and is one of the most common risk 
factors in obstetrics. Approximately 50% of pregnant women are either overweight 
(BMI >25 – 30) or obese (BMI >30). 25 In Australia, the rate of obesity in pregnancy 
was 46% wherein 26% are overweight and 20% were obese.26 
Prior to conception, obesity reduces fertility. This fertility reduction is secondary to 
reduced quality of fertilised egg that affects embryogenesis   in early gestation.27-28 
Maternal and fetal assessment during antenatal, intrapartum and postnatal management 
has increased complexity due to technical difficulties and limited resources in 
particular the extremely obese patients. Furthermore, there is higher rate of perinatal 
morbidity and long-term health problems of offspring of obese pregnant women. 
2.1.2. Body mass index 
There is no consistent definition of obesity in pregnancy. Women with ideal body 
weight of more than 110-120% or with a BMI greater than 30 kg/m2 considered obese. 
Body mass index is calculated as weight in kilograms divided by height in meters 
squared (kg/m2). It is not a perfect measure as it does not take into consideration other 
demographic information like ethnicity and age but is considered to be useful measure 
of obesity in the general population.29 Most obstetric units in Australia and New 
Zealand uses weight prior to pregnancy but unavailable or unknown.  BMI is calculated 
otherwise at the first booking in visit. According to World Health Organization (WHO) 
criteria, the table below is the classification of BMI.  
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Table 2.1. WHO BMI Classification29 
Classification BMI (kg/m2) 
Underweight  < 18.50 
Normal range  18.50–24.99 
Overweight  ≥ 25.00 
Pre-obese  25.00–29.99 
Obese class I  30.00–34.99 
Obese class II  35.00–39.99 
Obese class III  ≥ 40.00 
 
There is paucity of high level evidence in terms of pregnancy management in obese 
patients. The Royal Australian and New Zealand College of Obstetricians and 
Gynaecologists have revised the guideline for Management of Obesity in Pregnancy. 
The new guideline was based on consensus recommendation. The Royal College of 
Obstetricians and Gynaecologists released in November 2018 the updated guidelines 
for obesity in pregnancy.  
2.1.3. Weight gain  
Optimal management of gestational weight gain is lacking. Pregnancy weight gain 
goals should be planned by expecting mothers based on their BMI prior to pregnancy. 
Pregnant women should aim for an ideal body weight prior to contemplating 
pregnancy. Women can be questioned and advised about their exercise and diet during 
their consultation. Referral for nutritional counselling can be a useful for women not 
meeting the recommended weight gain. The Institute of Medicine (Table 2.2)30 
recommend a goal gestational weight gain of 11.5 to 16 kg in women with a normal 
weight before pregnancy, but obese women should only gain 5 to 9 kg during 
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pregnancy. The new guideline was based on observational research, until further 
evidence is presented, having healthy diet as may be more appropriate than prescribed 
weight gain goals. 
Table 2.2. Institute of Medicine weight gain recommendation during pregnancy30 
 
2.1.4. Complications 
Pregnant women with a BMI >30 and their babies are at risk of the complications in 
comparison to women with normal weight prior to pregnancy weight. Table 2.3 
summarises the complications associated with obesity in pregnancy. 
 
 
 
 
 
Classification BMI (kg/m2) Singleton 
pregnancy 
total weight 
gain range 
Rates of weight 
gain in second 
and third trimester 
(kg/week) 
Underweight   <18.5 12.5-18 kg 0.51 (0.44- 0.58) 
Normal 18.5-24.9  11.5-16 kg 0.42 (0.35- 0.50) 
Overweight 25-29.9  6.8-11.3 kg 0.28 (0.23-0.33) 
Obese: (all classes) 
     Class 1 
     Class 2:  
     Class 3: 
≥30 
30-34.9 
35-39.9 
BMI >40 
5-9.1 kg 0.220.17-0.27) 
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Table 2.3. Complications of obesity in Pregnancy 
Maternal Fetal/neonatal/childhood 
Miscarriage  Stillbirth 
Gestational diabetes  Congenital anomalies 
Pre-eclampsia, gestational hypertension Macrosomia 
Venous thromboembolism  
Induction of labour  Prematurity 
Caesarean section, operative vaginal 
delivery 
Neonatal death 
Anaesthetic complications Birth injuries including shoulder 
dystocia 
Wound infection, endometritis  
Breastfeeding issues Obesity and metabolic disorders in 
childhood 
 
2.1.4.1. Miscarriage 
Risk of miscarriage is increased in obese women. Study by Lashen et al identified an 
odds ratio for spontaneous abortion of 1.2 (95% CI 1.01 to 1.46) for obese women 
(BMI >30 kg/m2).31 
2.1.4.2. Gestational diabetes 
Gestational diabetes (GDM) is increased in obese pregnant women. Pregnant women 
with normal BMI have 0.9% absolute risk for GDM and 3.1% for overweight women. 
Obese and extremely obese women are 2-3x at increased risk of GDM in comparison 
with the overweight pregnant women with an absolute risk of 6.7% and 9.3% 
respectively. 32 
	 7	
2.1.4.3. Hypertensive disorders of pregnancy 
Risk in developing hypertensive disorder in pregnancy is doubled in those women who 
are overweight. 32 
2.1.4.4. Venous thromboembolism 
The United Kingdom Obstetric Surveillance System found a higher risk of 
thromboembolic events in the antenatal period for those pregnant women with BMI 
>30 kg/m2 with odds ratio of 2.65.  RCOG recommends thromboprophylaxis 
antenatally and postnatally.32 
2.1.4.5. Intrapartum complications 
2.1.4.5.1. Shoulder dystocia and macrosomia 
Sheiner et al found that women with BMI above 30 kg/m2 had an increased risk of 
LGA babies with an odds ratio of 1.4 without increased risk for shoulder dystocia. 31 
The detection of fetal macrosomia on ultrasound has been associated with increased 
rates caesarean section and labour induction.33 
2.1.4.5.2. Caesarean section 
Obese women have higher risk of caesarean section as previously mentioned.32 
Technical difficulties in performing the caesarean section are increased in comparison 
to women with normal weight. Caesarean section delivery unadjusted odds ratio is 1.46 
for overweight women and 2.05 for obese women.34 
2.1.4.5.3. Anaesthetic complications 
Epidural complications and respiratory impairment with the use of spinal anaesthesia 
is increased with maternal obesity including intubation difficulties and sleep 
disordered breathing making general anaesthesia challenging. It is recommended to 
have anaesthetic review in the antenatal period.32 
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2.1.4.6. Postpartum complications 
There is increased risk of bleeding in the postpartum period largely due to increased 
induction rates, prolonged labour and operative deliveries. Endometritis, breastfeeding 
issues and postnatal depression also common.32 
2.1.4.7. Perinatal outcomes 
The risk of congenital anomalies is increased with obese patients in comparison with 
women with normal BMI. The proportions of offspring with any major congenital 
abnormality were 3.4% for overweight mothers, 3.8% for mothers in obesity class 1, 
4.2% for mothers in class II obesity and 4.7% in obesity class III mothers.35 This can 
be attributed to dietary deficiencies like folate, in utero changes and technical 
challenges in assessment of fetal anatomy on routine fetal morphology scan in the 
second trimester due to lower antenatal detection rates of malformations. 
Women with BMI ≥35 kg/m2 have higher rates of stillbirth with odds ratio of 2.79.36 
This observation was believed to be due to decreased perception of fetal movements, 
hyperlipidaemia wherein blood flow in the placental circulation is compromised, and 
increased incidence of sleep disordered breathing leading to reduced placental blood 
flow and oxygenation.  
There is a growing evidence that in utero environment can predict potential health 
related issues. This includes obesity, hypertensive disorders and diabetes in the 
neonatal, childhood, and adult life.37 
2.1.5. Recommendations  
There are several recommendations from different countries regarding management of 
obesity in pregnancy. The Society of the Obstetricians and Gynaecologists of Canada 
published these recommendations as a useful guide:38 
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1. Regular medical examinations including gynaecologic review prior to pregnancy 
allows the opportunity to counsel issues pertaining to weight loss. It is ideal to have 
a normal BMI that is less than 25 kg/m2 prior to pregnancy.  (III-B) 
2. Height and weight prior to pregnancy should be used to calculate the BMI. An 
obese patient is defined as having BMI >30 kg/m2. This information can allow 
education and discussion about health associated risks of obesity in pregnancy. The 
discussion should include diet, nutrition and weight gain pregnancy. (II-2B) 
3. Associated medical risks including cardiac and pulmonary disease, hypertension, 
diabetes, and sleep disturbed breathing should be discussed at every opportunity. 
These risks can be reduced with regular exercise, early screening for gestational 
diabetes and prophylactic low dose Aspirin to reduce risk of preeclampsia. (II-2B) 
4. Appropriate screening should be conducted due to the increased risk of fetal 
congenital abnormalities in obese patients.  (II-2B) 
5. The BMI should be taken into consideration by the obstetric care provider when 
referring for second trimester fetal morphology assessment. Routine morphology 
scan typically undertaken at 20-22 weeks gestation. (II-2B) 
6. There is increased caesarean section rates with reduced success rates for vaginal 
delivery after caesarean section with obese women. (II-2B) 
7. Anaesthetic antenatal review should be organised for pain relief options and safety 
of regional anaesthesia. (III-B) 
8. Venous thromboembolism risk should be assessed and thromboprophylaxis should 
be individualised on obese patients.  (III-B) 
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Preconception nutrition, supplementation with high dose folic acid 5 mg daily and 
exercise information should be part of the consultation and this should be reemphasised 
antenatally and postnatally on women with high BMI. This will enable ongoing 
support on these women regarding suitable weight management from preconception 
until the postpartum period.39 
       Table 2.4. Evidence statements and grading of recommendations38 
Quality of evidence assessment  Classification of recommendations 
I: Evidence obtained from at least 
one properly randomized 
controlled trial  
A. There is good evidence to 
recommend the clinical preventive 
action     
II-1:  Evidence from well-designed 
controlled trials without 
randomization 
B. There is fair evidence to 
recommend the clinical preventive 
action 
II-2:  Evidence from well-designed 
cohort (prospective or 
retrospective) or case-control 
 studies, preferably from more 
than one centre or research group   
C. The existing evidence is 
conflicting and does not allow to 
make a recommendation for or 
against use of the clinical preventive 
action; however, other factors may 
influence decision making 
II-3:  Evidence obtained from 
comparisons between times or 
places with or without the 
intervention.   
 D. There is fair evidence to 
recommend against the clinical 
preventive action 
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III: Opinions of respected 
authorities, based on clinical 
experience, descriptive studies, or 
reports of expert committees 
 E. There is good evidence to 
recommend against the clinical 
preventive action 
 L. There is insufficient evidence to 
make a recommendation; however, 
other factors may influence decision-
making  
 
 
2.2. Extreme Obesity in Pregnancy 
Extreme obesity is defined as a BMI ≥ 50.00 kg/m2. Women in this category are at 
increased of adverse feto-maternal outcomes during the peripartum period when 
compared to class I and class II obese women.37 In addition, logistic issues become 
more apparent with increasing BMI. Therefore, it is important to ensure clinical follow 
up and screening for potentially modifiable outcomes like fetal macrosomia or fetal 
growth restriction (FGR). GDM and preeclampsia are of paramount importance in 
women with extreme obesity. Associated maternal and perinatal adverse outcomes 
with obesity have been reported, but this information is lacking in patients with 
extreme obesity.  
A national population-based cohort study in Australia by O’Sullivan et al using the 
Australasian Maternity Outcomes Surveillance System was conducted in 2010. The 
median BMI was 52.8 kg/m2 with an incidence of 2.1/1000 pregnant women with 
majority in the public system (96.2%), 36% coming from low socio-economic 
population and almost 24% are smokers. Furthermore, medical and pregnancy adverse 
	 12	
outcomes are increased for these women with extreme BMI with an adjusted odds ratio 
of 2.89 and 2.42 respectively. The caesarean section rate was 51.6% and admission to 
high dependency unit or intensive care unit was 6.2%.  Newborns from extremely 
obese patient had significantly higher rates of macrosomia with birthweight (BW) 
≥4500g, hospital transfer and admission to Neonatal Intensive Care Unit (NICU). 
Prematurity and perinatal mortality is not substantially increased. 41 
Women with extreme BMI are at increased risk of morbidities including their 
offspring. Strategies should address weight gain before and during pregnancy in a 
multidisciplinary team approach.  Training of clinicians within the health services is 
also important to deliver the best care for the patients. Surgical options like 
laparoscopic band, gastric sleeve or bariatric surgery prior to pregnancy should be 
considered. 
2.3. Maternal nutrition  
There are immense physiologic changes in pregnancy for the development and growth 
of the fetus. It is important to have the right nutritional intake to meet these demands. 
Pregnancy care should include nutritional assessment prenatally and during pregnancy. 
This will optimise the dietary requirements and changes needed to enhance maternal 
and child health prior to conception. Ongoing assessment and counselling should 
continue throughout pregnancy with ongoing input from relevant allied health 
practitioners best performed with multidisciplinary team approach. This team will 
include the obstetric provider and a dietitian who will be more involved in nutritional 
counselling and education. Nutritional assessment starts from history and physical 
examination. Background history of cigarette smoking, alcohol, and illicit drugs can 
be detrimental to patient’s health and adverse effects on the fetus. History bariatric 
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surgery makes the pregnant women at risk of micronutrient deficiencies and dumping 
syndrome.  
Survey form for daily routine diet on pregnant women will give more information on 
needed supplementation for dietary deficiencies. Regular follow ups should be 
organised about certain dietary issues to prevent nutritional deficiencies. Examples of 
potential problems include missing and reducing food, intake of artificial sweeteners, 
sweetened beverages, special diets like vegan diets, low intake of calcium foods, 
vegetables or fruits and high consumption of food with high sugar and fat. A good 
combination of fruit and vegetables, whole grains, low-fat dairy products and protein 
are recommended for a balanced daily diet.  
BMI should be calculated at the first booking in visit. Physical examination should 
include looking for clues of poor nutrition like brittle and dry hair, poor dentition, easy 
bruising and signs of poor wound healing. Patients with eating disorders like bulimia 
may have enlarged glands like the parotid gland and poor dentition. On the other hand, 
anorexia can result in menstrual disturbance dry skin and bradycardia.  
Laboratory investigations may include checking for signs of anaemia with ferritin 
levels, haemoglobin and haematocrit. Those history of malabsorption syndrome (celiac 
disease, inflammatory bowel disease) or bariatric surgery should be screened for folate 
and vitamin B12 deficiencies. Vitamin D levels should be checked for those with 
minimal sun exposure of skin, history of malabsorption, or other risk factors for 
vitamin D deficiency like dark skinned people. 
2.3.1. Pregnancy nutrition recommendations 
The important factors of healthy diet during pregnancy include a balanced dietary 
intake, vitamins and mineral supplementation, appropriate weight gain in pregnancy, 
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smoking cessation, alcohol abstinence and avoidance of other harmful substances and 
food handling precautions.42 
Pregnant women are advised to have additional 340 kcal/day in the second trimester 
and 450 kcal/day in the third trimester. Recommended dietary allowance is summarised 
on Table 2.5. This is recommended for women with normal weight and singleton. 
Whether this energy prescription is suitable for overweight and obese women is 
unknown.  
Table 2.5. Recommended Dietary Allowance in Pregnancy and Lactation43,44 
 Pregnancy Lactation Upper limit for 
pregnancy and 
lactation 
Fat-soluble vitamins    
Vitamin A 770 mcg 1300 mcg 3000 mcg 
Vitamin D 600 IU (15 mcg) 600 IU (15 mcg) 4000 IU (100 mcg) 
Vitamin E 15 mg 19 mg 1000 mg 
Vitamin K 90 mcg 90 mcg Not determined 
Water-soluble 
vitamins 
   
Vitamin C 85 mg 120 mg 2000 mg 
Thiamine 1.4 mg 1.4 mg Not determined 
Riboflavin 1.4 mg 1.6 mg Not determined 
Niacin 18 mg 17 mg 35 mg 
Vitamin B6 1.9 mg 2 mg 100 mg 
Folate 600 mcg 500 mcg 1000 mcg 
Vitamin B12 2.6 mcg 2.8 mcg Not determined  
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Minerals    
Calcium 1000 mg 1000 mg 2500 mg 
Phosphorus 700 mg 700 mg 4000 mg 
Iron 27 mg 9 mg 45 mg 
Zinc 11 mg 12 mg 40 mg 
Iodine 220 mcg 290 mcg 1100 mcg 
Selenium 60 mcg 70 mcg 400 mcg 
 
Antenatal dietary and lifestyle intervention trial on obese and overweight pregnant 
women was published in 2015 by Grivell et al, the Limit trial.45 This randomised 
controlled trial found that there is evidence of fetal growth modifications following 
diet and lifestyle changes. The intervention includes a balanced diet consisting of a 
good mix of carbohydrates, fat and protein, high fibre intake with a reduction saturated 
fats and refined carbohydrates.45 It also recommended to have two servings of fruit, 
five servings of vegetables, and three servings of dairy each day.46 Lifestyle changes 
include regular exercise like walking.47 Fetuses of women with lifestyle and dietary 
modification have significantly higher  mean mid-thigh fat mass with a slower rate of 
subscapular fat tissue accretion. The intervention group were found to have an overall 
improvement in their dietary consumption with a resultant decrease in neonatal BW of 
>4.0 or >4.5 kg.  
2.4. Maternal body composition measurements in pregnancy 
Upper body and lower body fat has different functional profiles. The upper body fat 
has been closely linked with cardiovascular risk and metabolic health issues like type 
2 diabetes mellitus whereas the lower body fat has opposing role having a more 
protective function.48 A reduction in upper-body fat and an increase in lower-body fat 
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may therefore result in a more favourable phenotype of adipose tissue distribution. The 
distribution of body fat has been found to be related to metabolic disorders. Vague et 
al49 reports that there is a close association between central fat accretion with diabetes, 
atherosclerosis, gout, and uric calculus disease than peripheral adiposity. Kissebah et 
al47 have classified fat distribution in women on the basis of the ratio of waist to hip 
circumferences. A high waist to hip ratio has been linked with hypertriglyceridemia, 
hypertension, hyperinsulinemia or glucose intolerance.  In addition, ischaemic heart 
disease is better predicted by waist to hip ratio.50  
There are several methods in evaluating body composition of pregnant women 
according to gestation and gestational weight gain. These methods are prone to 
measurement error and limited by availability of methods to obtain differences 
between fetal and maternal compartment and analyse this as a single unit. The majority 
of the available methods can only estimate whole body fat although some of these 
methods can provide regional body fat composition. Widen et al have summarised the 
methods in measuring the maternal body composition in pregnancy (Table 2.6).51  
Table 2.6. Methods for estimating changes in body composition in pregnancy 51 
Method  
 
Participant 
complexity 
Technical 
complexity 
Source of Error 
Anthropometry 
skinfold 
thickness  
 
Simple  Simple Prone to error related to 
compressibility of skinfold, 
oedema. Evaluation of total body 
fat available for only 
certain gestation 
	 17	
Total body water 
(TBW)  
 
Simple Specialized 
instruments 
Hydration of fat-free mass. Unable 
to disentangle the maternal–fetal 
unit 
Underwater 
weighing  
Complex Specialized 
instruments 
Unable to disentangle the 
maternal–fetal unit 
Air displacement 
plethysmography 
(ADP/BodPod) 
Complex Specialized 
instruments 
Unable to disentangle the 
maternal–fetal unit 
Magnetic 
resonance 
imaging (MRI) 
Simple Specialized 
instruments 
Methods have not been developed 
for pregnancy; therefore, the source 
of error is not fully understood 
Bioelectrical 
impedance 
analysis 
(BIA) 
Simple Specialized, 
portable 
equipment 
 
 
Has not been validated against 
reference methods in pregnancy. 
Unable to disentangle the 
maternal–fetal unit 
Dual energy X-
ray 
absorptiometry 
(DEXA) 
Simple—
for use 
in prenatal 
and 
postnatal 
Specialized 
instrument 
Not suitable during pregnancy due 
to radiation exposure. Prone to 
error due to changes in the 
composition of lean tissue that may 
persist into the postpartum period 
Ultrasound Simple Specialized 
instrument 
 
Estimates regional adiposity. Has 
not been validated against reference 
methods in pregnancy 
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2.4.1. Anthropometry 
To ascertain adipose tissues on different body compartments, anthropometric 
measurements are undertaken which include skinfold measurement and 
circumferences to detect changes in adipose tissues including arm muscle and fat area. 
The mid-arm circumference is measured at four different sites with patient’s arm 
unsupported on the side. These different sites include the triceps and biceps skinfold 
on the posterior and anterior aspect of the arm respectively; subscapular skinfold is 
measured at the inferior angle of the scapula and the supra-iliac skinfold is just above 
the iliac crest. 
There are some studies that have described skinfold thickness changes in pregnancy in 
different population.52-56 Overall, it was reported that the changes in skinfold thickness 
in the pregnancy are highly variable across measurement sites. A study by Sidebottom 
et al found that skinfold thickness on the triceps, thigh and subscapular area decreases 
from prior conception to 6 weeks gestation.56 The skinfold thickness increases up to 
30-35 weeks.53,56 Few changes on skinfold thickness was reported at 38 weeks but 
noticed a continued increase on mid-thigh skinfold thickness.53 In the postpartum 
period, it was reported that there was rapid reduction on the skinfold thickness most 
likely due to the changes in hydration following delivery. In marginally 
undernourished women, there is a net loss in skin fold thickness in pregnancy due to 
increased skinfold thickness only in the early trimesters with a significant decrease in 
the third trimester.54  
The subcutaneous fat of the arm in well-nourished and undernourished women usually 
increases early trimester and declines in the last trimester.52, 53, 55 
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2.4.2.   Total body water  
The dilution principle is the usually used to measure total body water (TBW). This 
uses isotope-labelled water labelled with deuterium which estimates TBW in the 
combined feto-maternal unit. Patients were instructed to fast for at least 4 hours after 
the dose. Women may be reluctant to ingest the isotope but they can be reassured that 
this is safe in pregnancy. Performance of this whole process requires adequate 
refrigeration which may not be accessible to other institution. There has been no 
validation of reference methods according to gestation in pregnancy. Body weight, 
density and composition can be estimated from TBW.    
2.4.3. Densitometry 
Hydrodensitometry are non-invasive methods and has been used extensively in 
pregnancy. Assessment of the patient’s body mass is the whole maternal and fetal 
compartment, therefore the fetal compartment cannot be assessed separately. In order 
to reduce the amount of air trapping, tight clothing needs to be worn by the patient 
when submerged in the water which may be problematic for the pregnant patient 
especially in the last trimester. In addition, this method is not validated for women 
more than 250 kg. It is however the preferred method of measuring body composition 
in pregnancy due to its ease.  
2.4.4. Imaging  
2.4.4.1. Magnetic resonance imaging and computed tomography 
Magnetic resonance imaging (MRI) and computed tomography (CT) are utilised to 
evaluate body composition however CT scan use is limited in pregnancy due to 
exposure to radiation while MRI are still in its infancy. CT scan in the general 
population was studied by Fujioka et al58 where body composition was measured at 
the umbilical cord level. The visceral fat area to the subcutaneous fat ratio was 
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considerably correlated with the metabolic blood parameters with increased levels of 
glucose and triglycerides. These findings may be indicative of increased 
cardiovascular risk.58 
MRI is used increasingly in pregnancy for assessment of adiposity and other soft tissue 
evaluation. There are no associated risks to the use of MRI with a magnetic strength 
of 1.5 Tesla. Its safety in the early part of the pregnancy has not been well studied.59 
MRI use in pregnancy is also limited due to high cost, limited availability and 
expertise. Pregnant women may also be hesitant to be exposed to a magnetic field. 
Lastly, maternal obesity may limit the patient from fitting in the machine especially in 
the third trimester.  
2.4.4.2. Dual energy X-ray absorptiometry 
Bone mineral content can be assessed with the use of dual energy X-ray absorptiometry 
(DEXA), however it is not recommended for use in pregnancy due to radiation 
exposure.   
2.4.4.3. Bioelectrical impedance  
Bioelectric impedance is cheap and non-invasive technique for evaluating body 
composition. This equipment uses an alternating current with very low electric current. 
The water content of the body is used as a conductor. However, the estimates of total 
body water are influenced by cellular water content which vary in most women in each 
gestation.  
2.4.4.4. Ultrasound 
Ultrasound assessment of maternal subcutaneous fat in pregnancy has been used in 
several studies and to date, standardized protocols has not been developed. Thus, it 
poses challenges on how to track changes in maternal adiposity in pregnancy 
particularly, compressibility of tissue changes may influence ultrasound true estimates. 
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The increasing use of ultrasound in the hospital setting may provide insights on how 
to reliably measure the maternal subcutaneous fat in the pregnancy with ongoing 
studies. 
The abdominal subcutaneous fat is the most studied regional fat measurement on 
ultrasound. Assessment of abdominal visceral fat is considered as an important tool in 
assessing adverse health outcomes. The assessment of visceral adiposity with the use 
of ultrasound instead of CT was proposed in the 1990s by Armellini et al.60 Ribeiro-
Filho et al replicated the measurement of abdominal fat as previously described by 
Armellini et al on non-pregnant women ages 20-65. The abdominal fat was assessed 
by measuring the space between the outer surface of the rectus muscle and the skin 
while the visceral fat is evaluated by measuring the space between the internal surface 
of the rectus muscle and the aorta (Figure 2-1).   This study demonstrated that apart 
from CT scan, ultrasound is another good option for the measuring of intraabdominal 
fat on obese women.  
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Figure 2-1. Ultrasound measurement of maternal abdominal subcutaneous fat 
thickness60  
A prospective study on pregnant women by Kennedy et al directly measured maternal 
abdominal subcutaneous fat thickness.12 This was measured in the middle of 
abdominal wall superior to the symphysis pubis through the linea alba. Three 
measurements taken, one in the middle and two measurements lateral to it with 5mm 
distance then averaged out to get the mean subcutaneous thickness of the abdominal 
wall. Calipers were placed on the echogenic subcutaneous fat (Figure 2-2).  A high 
intraclass and interclass correlation of 0.98 between two operators suggestive of good 
reproducibility. The study demonstrated that SFT measured at morphology scan at 18-
22 weeks is a predictor of pregnancy complications like of diabetes and caesarean 
section. Maternal abdominal fat thickness was also reported to be unchanged in the 
early trimester of pregnancy in women with normal weight and underweight, however 
this was reduced significantly in obese and overweight patients.  
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Figure 2-2. Ultrasound measurement of maternal subcutaneous fat with 
anatomical landmarks12  
Maternal visceral fat measurement and BMI in the second trimester was correlated 
with fetal biometry by Lopes et al. This group used the measurement method first 
described by Armellini et al.  This study showed that maternal visceral fat accretion 
was positively correlated with all fetal biometry. 
2.5. Intrauterine growth and adipose tissue development 
The embryonic period is the time of organogenesis which largely completed by the 
end of 8th week gestation. After the completion of embryogenesis, most organs are 
grossly in a recognizable form. The fetal period is the phase of rapid growth and 
development of organ systems. Intense developmental activity occurs at 3-8 weeks 
gestation. From 9 weeks until birth is the fetal period where rapid growth is striking. 
During the earlier gestation, the fetal trunk development dominates in comparison with 
the fetal head. The entire fetal body has no hair and very thin due to the non-appearance 
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of body fat. Abdominal growth, head and face contour and development occur in the 
middle of pregnancy.  
The chronological analysis of fetal fat formation was first published in 1911.  
Poissonnet et al61 analysed the chronology of adipose tissue appearance and 
distribution in the human fetus. The group examined 488 abortuses and checked under 
microscope the appearance of adipose tissues.  This study found that the formation of 
adipose tissues commences as early as 14-24th weeks of gestation and begins in the 
head and neck, then advances to the trunk and finally to the limbs. Previous 
investigators62-63 have postulated that the last part of the pregnancy is the sensitive 
period of formation and development as most these tissues are deposited in all body 
parts. However, Poissonnet found that full maturation and deposition of fetal adipose 
tissue is in the second trimester.  
The adipocytes serve primarily as energy storage, these cells therefore can be a good 
marker of the fetus nutritional status. More information on in utero regulation of 
adipose tissue development and storage can be derived on subcutaneous fat 
measurement in newborns with abnormal intrauterine growth.  
2.6. Barker’s hypothesis 
David Barker proposed the idea that the 20th century prevalent cardiac disease in 
developed countries might have originated in utero.64 It was proposed that fetal growth 
restriction has lifelong physiological and structural effects that increases the risk of 
adult diseases. An interruption during the critical period of rapid fetal cell division can 
have permanent metabolic or structural changes. Small for gestational age fetuses will 
respond by counteracting the adverse in utero environment. To accommodate 
undernutrition, the fetus will use its own fuel to provide energy.65 This is evidenced by 
a reduction in intrauterine growth velocity which helps the fetus to endure the harsh in 
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utero environment by lowering its energy consumption. There is cerebral redistribution 
and increased blood flow to the heart and adrenal gland.66 There is also blood flow 
reduction to the liver, abdominal viscera and kidneys. Hormonal and endocrine 
changes are also evident for fetal adaptation to growth restriction. There is reduced 
insulin and insulin-like growth factors (IGF) with maternal undernutrition, which will 
also reduce fetal insulin, IGF and glucose concentrations with resultant slowing of 
growth velocity due to reduced mobilisation of glucose and amino acids.67 This 
metabolic disturbance can predispose offspring to adverse adult health outcomes due 
to aberrant fetal programming.  
The thrifty phenotype was proposed by Barker et al that offspring exposed to harsh in 
utero environment will benefit better if remained in a harsh environment after birth.  If 
there is rapid catch up in nutrition, these changes increase the risk of abnormal glucose 
metabolism and obesity. Therefore, those fetuses with intrauterine fetal growth 
restriction became overweight later in life have the greatest risk of cardio-metabolic 
health issues. This phenomenon has been confirmed in several studies in 
approximately half a million individuals. 
There is a significant interplay of genetic, metabolic, endocrine, maternal nutrition and 
vascular phenomenon for fetal growth. Obesogenic environment with fetal 
undernutrition and overnutrition can lead to lifelong fetal metabolic changes that 
increases the risk of diseases in later life. The Barker hypothesis postulates that the in 
utero environment that the fetus has been exposed to causes epigenetic changes that 
alters gene expression which predisposes the offspring to childhood and adult diseases.  
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2.7.  Ultrasound for fetal assessment 
2.7.1.  Introduction 
The term "ultrasound" refers to sound waves of higher frequencies that are greater than 
the human ear hearing frequency. Real-time imaging is commonly employed in 
obstetrics and gynaecology. This sonographic technique is very useful in imaging 
mobile structures like the fetus itself and fetal heart.  Modern advances in ultrasound 
have emerged in the recent years that have provided significant access to the fetus. 
Assessment of fetal well-being, growth and anatomy have greatly improved with 
accuracy with this modern technology. 
Ultrasound have certain limitations and these should be discussed with the patient 
including its benefits and purpose. It should only be performed if medically indicated. 
Obstetrical ultrasound provides information on the age of the pregnancy, number of 
fetuses, presence cardiac activity, placental localization, and anatomical survey of the 
fetus. Fetal anomalies can be detected with detection rates of 84% for lethal 
anomalies.68 Ultrasound examination can also provide information on abnormal 
growth pattern of the fetus and amniotic fluid volume.  
The American College of Obstetricians and Gynaecologists has recommended 
ultrasound examination for all women who are pregnant.69 Determining gestational 
age is accurately performed in the first trimester as well as aneuploidy screening which 
is typically performed at 11-13 weeks gestation.  Fetal anatomy scan is usually done 
at 18 to 20 weeks of gestation since the detection of fetal structural abnormalities are 
accurately identified with more advanced fetal development. 
Specific obstetrical indications for ultrasound examination are listed on Table 2.7 and 
Table 2.8 as well as specific components according to trimester on Table 2.9 and Table 
2.10. If a specific component of the examination is not adequately visualised or not 
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clear, follow-up examination required two to four weeks from last examination. This 
timeframe depends on the limitations and findings of the initial examination. Timing 
and frequency of ultrasound examination depends on indication especially for patients 
with high risk factors for adverse pregnancy outcome. 
 Table 2.7. Indications for first trimester ultrasound examination in pregnancy70 
To confirm the presence of an intrauterine pregnancy 
To evaluate a suspected ectopic pregnancy 
To evaluate vaginal bleeding 
To evaluate pelvic pain 
To estimate gestational age 
To diagnose or evaluate multiple gestations (eg, chorionicity) 
To confirm cardiac activity 
As adjunct to chorionic villus sampling, embryo transfer, or localization and 
removal of an intrauterine device 
To assess for certain fetal anomalies 
To evaluate maternal pelvic or adnexal masses or uterine abnormalities 
To screen for fetal aneuploidy  
To evaluate suspected hydatidiform mole or other gestational trophoblastic disease 
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Table 2.8. Indications for second and third trimester ultrasound examination in 
pregnancy70 
Screening for fetal anomalies 
Evaluation of fetal anatomy 
Estimation of gestational age 
Evaluation of fetal growth 
Evaluation of vaginal bleeding 
Evaluation of abdominal or pelvic pain 
Evaluation of cervical length 
Determination of fetal presentation 
Evaluation of suspected multiple gestation 
Adjunct to amniocentesis or other procedure 
Evaluation of a significant discrepancy between uterine size and clinical dates 
Evaluation of a pelvic mass 
Evaluation of a suspected hydatidiform mole or other suspected gestational 
trophoblastic disease 
Adjunct to cervical cerclage placement 
Suspected ectopic pregnancy 
Suspected fetal death 
Suspected uterine abnormalities 
Evaluation of fetal well-being 
Suspected amniotic fluid abnormalities 
Suspected placental abruption 
Adjunct to external cephalic version 
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Evaluation of prelabor rupture of membranes or premature labor 
Evaluation of abnormal biochemical markers 
Follow-up evaluation of a fetal anomaly 
Evaluation/follow-up of placental appearance and location, including suspected 
placenta previa, vasa previa, and abnormally adherent placenta 
History of previous congenital anomaly 
Evaluation of the fetal condition in late registrants for prenatal care 
Assessment for findings that may increase the risk of aneuploidy 
 
Table 2.9. Components of first trimester obstetric ultrasound71-74 
Gestational sac location and diameter (if no 
embryo identified) 
Presence or absence of a yolk sac (diameter) 
Presence or absence of an embryo 
Presence or absence of cardiac activity 
Crown rump length 
Number of embryos 
Amnionicity and chorionicity of multiple 
gestations 
Anatomic survey, as appropriate for gestational 
age 
Evaluation of the uterus, adnexa, and cul-de-sac 
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Table 2.10. Components of second and third trimester obstetric ultrasound73,75-76 
Presence or absence of fetal cardiac activity, fetal heart rate and rhythm 
Fetal number 
Fetal presentation 
Assessment of amniotic fluid volume 
Placental appearance and location 
Umbilical cord vessel number and placental insertion site, if technically possible 
Fetal biometry (biparietal diameter, head circumference, femoral length, abdominal 
circumference) 
Evaluation of the uterus, cervix, and adnexa when clinically appropriate 
Fetal anatomic survey 
Presence or absence of fetal movement 
Evaluation of each fetus of a multiple gestation 
 
Safety of ultrasound use in pregnancy have evolved from the time it was first used. 
Animal studies have shown potential harmful effects on applying extreme levels of 
ultrasound exposure to rodents.  However, follow up on children after 7 years found 
no significant adverse effects.77 Nevertheless, there should be ongoing review 
regarding safety of ultrasound in pregnancy .78 Its use in pregnancy should be for 
medical indications with the shortest possible time to limit exposure on the fetus. 
The primary concerns of the use of ultrasound technology are with respect to thermal 
effects and cavitation of tissue due to the production of gas-filled bubbles. The 
obstetric acoustic output should maintain a Thermal Index and Mechanical Index 
below 1.0. 78 
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Ultrasound is propagated by mechanical vibration of sound waves and heating of 
tissues. Mechanical vibration can lead to formation of gas bubbles or cavitation which 
typically happens at the interface of tissues and gas. This is not a significant factor for 
the use of ultrasound in pregnancy as the uterus is devoid of gas.  On the other hand, 
thermal effects may possibly affect the fetus. This can be reduced by using B mode 
especially in the early trimester when embryogenesis is taking place. This mode of 
imaging does not increase the temperature greater than 1 to 1.5 degree Celsius which 
is a safe range for the developing fetus.78 WHO published a systematic review 
regarding safety of B mode or Doppler ultrasound in pregnancy.79 It was reported that 
B mode was not associated with adverse pregnancy outcome, impairment of physical, 
neurological, cognitive and mental health and increased risk of childhood malignancy. 
A small increase non-righthandedness with male offspring was observed, but the 
association was weak.  This weakly associated non-righthandedness was also reported 
in a meta-analysis of three randomised controlled trials.80  
Spectral Doppler ultrasound uses higher energy than B mode which can potentially 
change tissue temperature especially at bone-tissue interface. Therefore, the use of 
Doppler ultrasound should be used with caution with limited dwell time and only for 
valid medical reasons.  
Timing and frequency of ultrasound in pregnancy is dictated by valid medical 
indications. No studies have found an association between the frequency and timing 
of prenatal ultrasound exposure and pregnancy-related risk factors for childhood 
developmental issues like autism spectrum disorder.81-83 
2.7.2. Dating scan 
Early pregnancy ultrasound’s role is to confirm a viable intrauterine pregnancy, 
establish a gestational age, document number of fetuses and establish chorionicity in 
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multiple pregnancies. This can be done transvaginally and transabdominally. However 
transvaginal imaging has higher resolution in comparison with transabdominal 
scanning and preferred by most clinicians as the imaging modality in the first trimester. 
First trimester sonographic assessment of crown rump length (CRL) gives the best 
accuracy in estimating age of gestation.84 Although the gestational sac size is the 
earliest sign of pregnancy that can be detected for assessment of age of gestation, the 
CRL is more precise in estimating the age of the pregnancy. The crown is the skin 
above the skull and the rump is the skin at the tip of the sacrum. Calipers are placed at 
the outer surface of the skin (Figure 2-3). CRL is measured to determine the expected 
date of delivery (EDD), the EDD derived from the earliest measurement of CRL 
becomes the patient's EDD, and this EDD is not changed based on subsequent 
biometry. For twin pregnancies, if there is a discrepancy between the twins in 
biometric measurements, the general consensus is that the EDD should be based on 
the measurements for the larger twin.85-86 For pregnancies conceived in vitro, the EDD 
may be based on factors other than sonography and LMP. 
 
 
Figure 2-3. CRL measurement 87 
	 33	
Ultrasound scan to estimate gestational age performed from 28 weeks onwards is less 
reliable in dating the pregnancy. This poses a difficult management plan for fetuses 
scanned in the third trimester with unknown age of gestation. This is commonly 
encountered in changing the date of the pregnancy in a small fetus that may be growth 
restricted.  Estimation of gestation age for women who present for the first time late in 
the pregnancy with uncertain dates was published by the Intergrowth-21 group in 2016. 
The group recommended ultrasound measurements of head circumference (HC) and 
femur length (FL) when dating the pregnancy outside the first trimester.88 
Dating scan is also a reliable way of identifying multiple gestations. Chorionicity 
determines outcome on twins and higher order multiples. This is best evaluated in the 
first trimester. Viability scan allows evaluation of maternal structures especially for 
patients presenting with abdominal pain with missed cycles. It enables detection of 
other gynaecologic pathology like ovarian torsion or rupture, haemorrhagic corpus 
luteum, degeneration of fibroids etc.  
2.7.3. Prenatal screening 
 2.7.3.1. Serum screening test 
Choosing the most appropriate screening test can be confusing because multiple 
options are available. Assessment of maternal serum biochemistry associated with 
Down syndrome in the first and second trimesters are widely available. 
The triple test is performed in the second trimester which includes alpha fetoprotein 
(AFP), human chorionic gonadotrophin (HCG), and estriol together with maternal age 
for Down syndrome assessment.  The quadruple test is also done at the same time as 
the triple test. This test incorporates inhibin levels with the triple test maternal serum. 
Fetuses with Down syndrome have reduced levels of maternal serum AFP and estriol 
levels are in about 30%.89 HCG and inhibin A levels are within normal limits in 
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unaffected pregnancies.90 This screening test for Down syndrome is available for 
pregnant women with late presentation for antenatal care. This test also screens for 
neural tube defects as AFP is included in the assessment. Detection rates for the 
maternal serum averages about 70% and 75% for triple test and quadruple test 
respectively. 
The uptake of these prenatal serum screening test in Australia is very low. For patients 
who missed in the first trimester screening, non-invasive prenatal testing and invasive 
testing remains an option to patients.  
 2.7.3.2. Combined first trimester screening 
The combined first trimester screens for Down syndrome, Patau syndrome and Edward 
syndrome. Down syndrome is the most common of the three syndromes and it is the 
primary target of prenatal aneuploidy screening. 
In the past, maternal age over 35 years old is the typical screening method for common 
trisomies like Down syndrome.  Invasive testing is usually offered to these women. 
The detection rate was less than 50% of women with advanced maternal age as the 
majority of Down syndrome affected fetuses came from a younger population.  
In the recent years, the combined first trimester screening was increasingly utilised due 
to its high sensitivity and low false positive rates. The combination of maternal 
biochemistry free beta HCG and pregnancy associated plasma protein – A (PAPP-A) 
with measurement of nuchal translucency is a good screening method. Incorporation 
of fetal nasal bone assessment, ductus and tricuspid flow and fetal heart rate have 
increased the detection rate to 95% in detecting Down syndrome and other trisomies 
with resultant decrease in invasive testing to 3%. 87 
Added advantages of the 11–13 weeks scan includes accurate estimation of the 
gestational age, early assessment of fetal structural abnormalities, diagnosis of 
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multiple gestations with increased sensitivity in the diagnosis of chorionicity. An 
important breakthrough in the recent years is the inclusion of risk assessment for early 
onset preeclampsia. It is important to emphasise that centres offering this screening 
test should have ongoing training and quality assurance to maintain high detection 
rates.  
The Fetal Medicine Foundation have outlined the protocol for measuring the nuchal 
translucency:87 
1. Screening between 11 to 13 weeks and six days with a CRL 45 and 84mm 
2. The magnification of the fetal head and thorax should occupy most of the screen. 
It is important to reduce the gain to minimise underestimation of the true 
measurements 
3. Mid-sagittal view of the face should include echogenic tip of the nose, fetal palate, 
diencephalon and nuchal translucency   
4. Fetus should be in a neutral position. Hyperextension of the fetal neck will have a 
falsely thick measurement while a hyperflexed neck will underestimate the fetal 
nuchal thickness  
5. Fetal skin and amnion must be differentiated 
6. Widest part of nuchal translucency that meets all criteria must be recorded with 
calipers placed on the inner borders of the nuchal thickness 
7. Nuchal translucency must be measured more than once 
8. In the presence of umbilical cord, nuchal translucency should be measured above 
and below the cord and record the average 
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Figure 2-4. Normal nuchal translucency (NB – nasal bone, NT – nuchal 
translucency)87 
 
Figure 2-5. Abnormal nuchal translucency (NT – nuchal translucency)86 
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 2.7.3.3. Nasal bone 
Majority of fetuses with Down syndrome and other common trisomies have hypoplasia 
or aplasia of the nasal bone on a routine combines first trimester screening at 11-13 
weeks. Detection rates for Down syndrome is greatly improved with evaluation of the 
nasal bone. (Figure 2-6) 
The Fetal Medicine Foundation assessment of nasal bone in the first trimester:87 
1. Screening between 11 to 13 weeks and six days with a CRL 45 and 84mm 
2. The magnification of the fetal head and thorax should occupy most of the screen 
3. Mid-sagittal view of the face should include echogenic tip of the nose, fetal palate, 
diencephalon and nuchal translucency   
4. Three distinct lines must be demonstrated: the first two lines resembling an "equal 
sign" with nasal bone that is more echogenic and thicker compared to the overlying 
skin. The third line is the tip of the nose 
5. Thin nasal bone suggests hypoplastic or absent  
 
Figure 2-6. Nasal bone is thicker and more echogenic than the overlying skin86 
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 2.7.3.4. Ductus venosus flow 
The presence of a-wave during cardia atrial contraction is of paramount importance in 
interrogating the ductus venosus and its presence is considered normal (Figure 2-7). 
Whereas if the a-wave is reversed or absent, this is an abnormal finding  (Figure 2-8). 
There is increased association with adverse pregnancy outcomes, chromosomal 
abnormalities and cardiac anomalies with high resistance flow in the ductus venosus 
on a routine scan at 11-13 weeks gestation. Pulsatility index for veins (PIV) is one of 
the parameters that may signal increased surveillance for fetal wellbeing.  
Ductus venosus blood flow evaluation in first-trimester combined screening improves 
the detection rate for trisomy 21 to 95% with a false positive rate of 3%. Below is the 
suggested protocol for ductus venosus assessment in the first trimester:87 
1. Screening between 11 to 13 weeks and six days with a CRL 45 and 84mm 
2. The examination should be carried during fetal quiescence 
3. Sagittal view color flow mapping of the umbilical vein, ductus venosus and fetal 
heart (Figure 2-9) 
4. Pulsed Doppler sample gate of 0.5-1.0 mm and placed in the aliasing area 
5. Insonation angle is less than 30 degrees 
6. Low frequency (50-70 Hz) filter to avoid obscuring the a-wave with a speed sweep 
of 2-3 cm/sec  
7. Manual tracing of the ductus venosus PIV and value is recorded  
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Figure 2-7. Ductus venosus a wave present87 
 
Figure 2-8. Ductus venosus reversed a wave87 
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Figure 2-9. Sagittal view of fetal torso with color mapping of the ductus venosus86 
2.7.3.5. Tricuspid valve flow 
Fetuses with chromosomal abnormalities particularly Down syndrome, Patau 
syndrome and Edward syndrome may present with tricuspid valve regurgitation on a 
routine combined first trimester screening.  This can also be found in fetuses with 
structural heart abnormalities. Tricuspid regurgitation is found in almost 60% of Down 
syndrome fetuses and 30% of fetuses with Patau and Edwards syndrome.  Tricuspid 
regurgitation is however a normal finding in 1% of normal fetuses. Its inclusion in the 
combined first trimester screening increases the detection rate for Down syndrome to 
95% with false positive rate of 3%. Below is a suggested protocol from the Fetal 
Medicine Foundation: 87 
1. Screening between 11 to 13 weeks and six days with a CRL 45 and 84mm 
2. Obtain apical four-chamber view of the fetal heart 
3. Pulsed-wave Doppler sample gate of 2.0 to 3.0 mm across the tricuspid valve with 
an angle is less than 30 degrees with a sweep speed of  2-3 cm/s (Figure 2-10) 
4. Velocity of over 60 cm/s is consistent with tricuspid regurgitation 
5. Assess the valve at least three times 
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Figure 2-10.  Four chamber heart view for tricuspid flow interrogation87  
 
Figure 2-11. Normal tricuspid valve waveform with a velocity less than 60 
cm/sec87 
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Figure 2-12. Abnormal tricuspid valve waveform with a velocity above 60 
cm/sec87 
2.7.4. Morphology scan 
One of the advantage of combined screening in the first trimester for chromosomal 
anomalies is the assessment of fetal anatomy for early detection of structural 
anomalies. With the advances in technology, increasing experience and training in 
obstetric ultrasound, there is increased detection rates of major structural conditions 
early first trimester of the pregnancy. Checklist of structures to be assessed should be 
completed and if in doubt should be followed up at an appropriate time.  The 
International Society of Ultrasound in Obstetrics and Gynaecology91 published 
ultrasound guidelines summarising the details of early evaluation of the fetal anatomy. 
The following structures should be identified: the cranium, falx and choroid plexus of 
the fetal head; lungs, four chamber cardiac view and diaphragm of the fetal chest; 
stomach, cord insertion and bladder of the fetal abdomen; and long bones, hands and 
feet.  
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Structural anomalies commonly detected in the first trimester are cranial abnormalities 
like anencephaly; abdominal wall defects like gastroschisis and omphalocoele, 
hypoplastic heart anomalies; mega bladder and limb body wall defects.92-93 Other 
conditions most probably will not be detected until advanced gestation like skeletal 
anomalies, face and palatal defects, diaphragmatic or chest anomalies and other heart 
abnormalities. About 25% of fetal anomalies are not evident in the first trimester like 
renal tract abnormalities, lung lesions, brain conditions like absent cavum septum, 
echogenic lung lesions like congenital diaphragmatic hernia or congenital pulmonary 
airway malformtion and fetal tumours.93 
The fetal morphology scan is best performed at midgestation. Although, this can also 
be done at any time if clinically indicated. The use of ultrasound is not without 
limitations, thorough evaluation of the fetus is not always achieved in one visit because 
of fetal position and maternal obesity.  
The use of ultrasound examination of the fetus is generally safe in pregnancy, however 
its use should be carried out only when clinically indicated. In lined with the as low as 
reasonably achievable principle (ALARA principle), with the minimum acoustic 
output and shortest possible time should be adhered at all times.94 
Second trimester scan should include evaluation of position or presentation of the 
fetus; volume of the amniotic fluid; presence or absence cardiac activity; position of 
the placental; fetal growth parameters; detection of multiple pregnancy and 
chorionicity; and fetal morphology assessment.  
This should also include the gestational age assessment which includes head 
measurements the biparietal diameter (BPD) and HC; abdominal circumference (AC) 
and FL. The resultant measurements should be recorded and will correspond to an 
estimate of the fetal weight. If ultrasound measurement differs from the age of 
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gestation based on last menstrual period (LMP) more than 2 standard deviation, dating 
should be reassessed and fetal surveillance for fetal well-being and abnormal growth 
trajectories should be included in the management plan. If the patient is not sure of her 
last menstrual period and did not have any prior scans in the pregnancy, date of 
delivery should be based on ultrasound measurements of the fetal HC and FL.88 
Maternal structures should be evaluated. This includes assessment of the length of the 
cervix and adnexal structures.  
The Fetal Medicine Foundation fetal anatomy survey outlines the following structures 
for completion of the assessment.86 Please see Table 2-11. 
Table 2-11. Fetal anatomy checklist 87 
Organ system Structures 
Head • Transverse view of anterior brain fossa: level of 
cavum septum pellucidum with HC, BPD, 
cerebral ventricle measurements  
• Posterior brain fossa: cerebellum and cisterna 
magna measurements (sub-occipital-bregmatic 
view) 
Face • orbits and the upper lip and maxilla (Transverse 
view) 
• face (profile) demonstrating the nasal bone 
(Sagittal view) 
Heart • Four-chamber view of the heart 
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• Outflow tracks of the heart 
• Fetal heart rate and rhythm 
Abdomen • AC measurement at the level of the stomach and 
umbilical vein (Transverse view) 
• Kidneys (Transverse view) 
• Umbilicus (Transverse or longitudinal view) 
• Bladder (Transverse or longitudinal view) 
Limbs • FL and Humeral length (HL) measurement 
(Longitudinal view) 
• Leg and foot (Longitudinal view) 
• Open hand 
Spine • Whole spine (Longitudinal view) 
• Sacral spine (Transverse view) 
Placenta • Position 
• Longitudinal view demonstrating the relation 
between the lower end of the placenta and cervix 
Maternal 
structures 
• Cervical length 
• Uterine adnexae 
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2.7.5. Fetal growth assessment 
Fetal assessment of growth is undertaken in the second and third trimester of the 
pregnancy. Clinical history and examination should be included in the evaluation. 
Serial fundal height measurements are normally undertaken in every clinical visit 
although may be limited with the lack of sensitivity in predicting appropriate growth of 
the fetus. So far, ultrasound is the optimal technique in the assessment of fetal well-
being and growth.  
Population-based growth studies have concluded that there is 30-50% BW variation 
secondary to genetic factors with environmental factors accounting for the majority of 
the cases. BW is influenced by parental genes but the maternal genes are more 
contributory than the paternal side.94  
Fetal growth velocity is defined as the rate of fetal growth over a given time interval. 
In terms of individual biometric measurements, the rate of change in BPD, HC, FL and 
AC initially peaks at 13, 14, 15, and 16 weeks, respectively, and then has a second 
acceleration at 19 to 22, 19 to 21, and 27 to 31 weeks, respectively.95 At around 35 
weeks, fetal weight velocity is at its maximum. The rate of normal growth velocity in 
singleton pregnancies increases from approximately 5 g/day at 14 to 15 weeks of 
gestation to 10 g/day at 20 weeks and 30 to 35 g/day at 32 to 34 weeks, after which the 
daily increase in weight decreases.96 
 2.7.5.1. Biometry 
 2.7.5.1.1. Biparietal diameter and head circumference 
Transverse view of fetal cranium, BPD and HC are measured, including cavum septum 
pellucidum, the falx cerebri, and thalami. The BPD is measured from the outer to inner 
edge of parietal bone (Figure 2-13).  The HC is measured along the edge of the outer 
skull bone (Figure 2-14).  
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Figure 2-13. Transverse view for BPD measurement (F - flax, CSP – cavum 
septum pellucidum, T – thalami)97 
 
Figure 2-14. Transverse view for HC measurement97 
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  2.7.5.1.2. Femoral length and humeral length 
The long bones are measured on a longitudinal view and calipers placed on the 
diaphysis with the bone imaged across the beam axis. The calipers are placed along 
the diaphyseal shaft excluding the epiphysis (Figures 1-15 and Figure 2-16).   
 
Figure 2-15. Longitudinal view for HL measurement97 
 
Figure 2-16. Longitudinal view for FL measurement97 
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2.7.5.1.3. Abdominal circumference 
Assessment of fetal growth is best predicted with the AC measurement. There should 
be an interval of 2-3 weeks to assess growth velocity to avoid underestimating the fetal 
size. Transverse measurement of the fetal abdomen is measured at the level of the 
stomach and umbilical vein. The fetal fat layer must be included (Figure 2-17).  
 
Figure 2-17. Transverse view for AC measurement (SP – spine, S – stomach, V – 
umbilical vein) 97 
2.7.5.1.4. Estimated fetal weight 
No estimated fetal weight (EFW) formula has been found to be suitable across all 
weight ranges. Hadlock formula with HC, AC and FL and Hadlock formula with BPD, 
HC, AC and FL are two of the commonly used reliable methods. Both of these 
formulas have low margin of error in estimating the true BW of the neonate.97 
Accurately dating the pregnancy is critical to the diagnosis of fetal growth restriction 
(FGR). The use of growth centiles to define FGR is complicated because it does not 
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differentiate a growth restricted fetus from constitutionally small fetuses.  70% of 
fetuses with weight less than the 10th centile are small secondary to maternal 
constitutional factors like age, ethnicity, parity, or body mass index. Perinatal mortality 
and morbidity on these fetuses is not significant comparted to pathologically small 
fetuses.94 Furthermore, the use of percentiles requires a suitable reference guide. 99	 
When all fetal biometries are globally less than expected for gestational age, this is 
considered symmetric FGR (20-30% of FGR). It is thought to result from a pathologic 
process manifesting early in gestation. Whereas, asymmetric FGR comprises majority 
(70-80%) of the FGR fetuses. Asymmetric FGR presents with decreased AC 
measurement relative the head circumference. This manifest mainly in the late 
trimester evidenced as well by cerebral redistribution with increased preferential flow 
to the heart and adrenals with resultant decrease in the blood flow lungs, bowel, skin 
and kidneys.100  
Sonographic estimation of fetal weight <3rd, 5th, or 10th percentile is the single best 
finding on which to base the diagnosis of FGR. Maternal history, customized growth 
curve, amniotic fluid volume and uterine artery Dopplers may help to differentiate 
between constitutionally small fetus from growth restricted fetus. The Fetal Growth 
Longitudinal Study developed an international growth and size standard. This was a 
based on a prospective study of over by 4000 healthy.101 From 14 weeks gestation until 
42 weeks gestation, ultrasound examinations were obtained every 5 weeks, and 
biometric measurements were used to derive the best fitting curves for the 3rd, 50th, 
and 97th centiles. The  World Health Organization published charts for fetal 
growth and common ultrasound biometric measurements. This is based on longitudinal 
data from 10 countries.102 Regardless of the standard used, EFW performed within one 
to two weeks of delivery is more reflective of actual BW. The sensitivity, specificity, 
	 51	
positive, and negative predictive values of EFW for FGR <10th percentile are 
approximately 90, 85, 80, and 90%, respectively, when performed close to delivery.103 
    2.7.5.2 Amniotic fluid volume 
Amniotic fluid volume assessment using the four quadrant or deepest vertical pocket 
is preferred technique. This should be analysed according to age of gestation. The 
deepest vertical pocket, is faster to perform and correlates with perinatal outcome in a 
population of low-risk women.100 Oligohydramnios can be recorded if vertical 
measurement is less than 2 cm. A vertical pocket of more than 10 cm is considered 
polyhydramnios.  
2.7.5.3. Doppler studies 
Maternal and fetal vessel flow assessment provides information about uteroplacental 
blood flow and fetal adaptation to physiologic changes. The information derived from 
velocity waveforms varies according to the specific vessel interrogated: 
• Flow patterns in the umbilical cord may be reflective of placental function. This 
can be assessed with pulsatility or resistance index and presence or absence of 
diastolic flow. There will be an increased resistance in the umbilical cord flow 
pattern if 30% of placenta is compromised. If there is no umbilical artery diastolic 
flow or the flow is reversed, about 70% of the placental vasculature is non-
functional. Reversed diastolic flow is associated with poorer neonatal outcomes 
than absent diastolic flow.103 
• Doppler assessment of the middle cerebral artery and ductus venosus have role in 
assessment of monochorionic twins, fetal anaemia, reduced fetal movement and 
FGR but is not routinely indicated.105 In the normally developing fetus, the blood 
flow to the brain is continuous with low resistance. There is redistribution of blood 
flow of the brain in the growth restricted fetus. The cerebroplacental Doppler ratio 
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(CPR) is the middle cerebral artery pulsatility or resistance index divided by the 
umbilical artery pulsatility or resistance index. A low CPR signifies fetal blood 
flow redistribution and is predictive of adverse neonatal outcome.105 
• Venous Doppler abnormalities are late, ominous circulatory findings in FGR.  
• An elevated pulsatility index in the fetal descending aorta is associated with FGR 
and increased perinatal morbidities like severe FGR, necrotizing enterocolitis, non-
reassuring fetal heart rate patterns. Perinatal mortality is also increased. This 
abnormal descending aortic flow may imply that almost two thirds the placenta has 
been obliterated. The sensitivity and specificity of absent end-diastolic flow in the 
descending aorta for prediction of FGR with fetal heart rate abnormalities are 
approximately 85 and 80%, respectively.106  
• The systolic/diastolic (S/D) ratio of the uterine artery is less that 2.7 in normal 
pregnancies after the 26th week of gestation. Notching of the uterine artery blood 
flow may predict disturbed fetal growth.107  
2.7.6. Fetal fat measurement 
2.7.6.1. Ultrasound 
Evaluation of the fetal subcutaneous thickness have evolved over the past 20 years. 
And to date, there are no standardised methods or techniques in measuring fetal fat. 
There are several methods available for assessing the fetal fat regions, particularly for 
the abdomen and extremities. Comparative analysis of different techniques at this 
present time has not been undertaken. Other research has evaluated the subscapular 
area, face and buttocks adipose tissue in addition to the above mentioned 
compartments. These fetal compartments contains fat stores, but which one 
predominates is not yet known. As mentioned in previous discussion in fetal fat 
development, the formation of fetal fat starts as early as 14-24 weeks. Therefore, it 
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follows that the second trimester is the important period for fat replication. Whether 
fat deposition in this critical period is the same in all population or differences exists 
between different maternal demographics like ethnicity and BMI. There are several 
maternal factors that can influence fetal growth and distribution of fetal fat like age, 
ethnic background, BMI, gestational weight gain, hypertension and diabetes.110 
Whether or not assessment of fetal fat will provide additional information on fetal fat 
distribution has not been explored on obese patients. There are numerous gaps and 
uncertainties in this evolving area that needs to be elucidated and determine if there is 
any clinical use. 
The use of ultrasound in pregnancy has been used extensively to assess fetal growth 
and well-being. The assessment of the weight of the fetus with the use of head, 
abdomen and long bones parameters provide information if fetal growth is appropriate 
or not. These fetal anthropometric measurements are limited by its low sensitivitity 
and specificity. It was reported to be as high as 25% error in determining the fetal 
weight due to measurement errors.108 Moreover, the biometric measurement of fetal 
abdomen can only predict less than 80% of macrosomic babies.109 Determination of 
fetal fat is still in its infancy. Reference ranges and standardised methods have not been 
elucidated well. Whether or not fetal subcutaneous thickness evaluation will be able to 
detect a fetus with increased perinatal morbidity and mortality is still unknown. And 
whether or not this additional fetal measurement will help in evaluating glycemic 
control on diabetic mothers.  
The evaluation of fetal fat have emerged to evaluate if it improves estimation fetal 
growth. A study by Elessawy et al110 explored the ability of third trimester abdominal 
fetal fat layer measurement in improving the detection of LGA fetus in women with 
GDM. This is in addition to the routine fetal growth parameters assessment, close 
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monitoring diabetes control and BMI.  Transverse view of the abdominal 
circumference was magnified and the fetal abdominal subcutaneous fat was measured 
(Figure 2-18). This study found that abdominal fetal fat layer of 0.48 cm and 0.59 cm 
at 34 and 37 weeks respectively, has a sensitivity of 60% and specificity of almost 
90%. This is useful for predicting LGA fetuses, in addition to routine fetal biometry.  
 
Figure 2-18. Measurement of abdominal fetal fat layer110 
Fetal abdominal fat thickness was also analysed in 100 singleton pregnancies by 
Skinner et al.107 Fetal abdominal fat was assessed together with the routine AC and 
amniotic fluid volume. The portion of the abdominal wall that was measured was close 
to the margins of the ribs measured in millimetres. The neonatal parameters were 
assessed during the first few days of life. This include actual BW, ponderal index, 
triceps and subscapular skinfold thickness. This study concluded that offspring with 
less than 5 mm thickness of the fat layer were more likely to have low amniotic fluid 
and smaller abdominal wall biometry compared to those fetuses with more than 5mm 
fat thickness. Moreover, fetuses with thinner abdominal fat thickness in utero have less 
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skinfold thickness on the regions of interest as mentioned above in the neonatal period. 
This study showed that there was good correlation between in utero assessment of fetal 
abdominal fat layer with amniotic fluid volume and AC and neonatal body composition 
measurements. On the other hand, Padoan et al108 analysed the fetal thigh subcutaneous 
fat on growth restricted fetus. Thigh fat area was the total limb area then subtracting 
the lean central area.113-114 Figure 2-19 showing on transverse view the thigh fat area 
measurement. This study showed that fetuses with FGR have reduced fat and lean mass 
compared with control group. This finding may be able to discriminate between a fetus 
with growth disturbance from a constitutionally small fetus.  
 
Figure 2-19. Schematic measurement fetal thigh fat and lean mass (M – muscle, 
SQ – subcutaneous) 113-114 
	 56	
An editorial paper by Schwartz et al115 in 2003 illustrated several fetal subcutaneous 
measurements using ultrasound. Several techniques have been investigated since 
1980’s. Jeanty et al116 were one of the first groups who measured the fat layer of the 
extremities. The accuracy of measurements fell short in the 1980s as advances in 
ultrasound are limited. Around the same time, Vintzileos et al117 described the normal 
range for fetal thigh and calf circumferences from 20 weeks gestation. The technique 
used by Deter et al.118 In 1997, Bernstein et al developed another method to assess fetal 
limb fat and this was replicated by Padoan et al as previously mentioned.  
In 1992, Hill et al119 measured the fat layer of the abdomen, mid-thigh and mid-calf to 
predict fetal growth disturbance. The area of interest was measured 2 cm lateral to the 
insertion of the umbilical cord on a routine AC measurement (Figure 2-20). Results 
showed that the abdominal fat layer measurement does not correlate with growth 
abnormalities for either growth restricted fetuses nor macrosomic babies. The 
deposition of fat may not be the same in all areas therefore a specific point of 
measurement may have overlooked the disparities between fetuses with different 
potential.  
 
	 57	
 
Figure 2-20. Fetal abdominal fat thickness measurement 2 cm lateral from the 
umbilical cord insertion (UCI)119 
In 1997, Petrikovsky et al120 performed similar measurements as Hill et al to predict 
fetal macrosomia. The difference in the technique employed by group was measuring 
the widest area of the abdominal wall. In this technique, the calipers are placed at the 
echogenic fat layer (Figure 2-21). These sonographic measurements are predictive of 
fetal overgrowth with abdominal fat thickness of ≥ 11 mm with positive predictive 
value of almost 95%.  In 1999, Gardeil et al121 hypothesized that determination of fetal 
fat thickness is a good predictor of growth abnormalities. A fetal fat thickness of <5mm 
will predict a neonate with a BW below the 10th percentile. This was replicated by 
Skinner et al as previously mentioned.  
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Figure 2-21. Fetal abdominal fat thickness measurement at its widest point 
anteriorly120 
Ulttrasound measurement of the fetal cheek and the buttom is studied less extensively. 
It was pioneered 1991 by the work of Abramowicz et al118 measuring the cheek-to-
cheek diameter on the assumption that its it is wider with fetuses with overgrowth 
because the cheeks bulge out. (Figure 2-22). 
 
Figure 2-22. Fetal cheek to cheek diameter measurement122 
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The buttocks of the fetus was qualitatively assessed by Matsumoto et al.123 This group 
performed a three-dimensional (3D) evaluation of fetal soft tissue on 52 fetuses. This 
was performed from 29 to 41 weeks gestation within one week of delivery. These 
fetuses were given a score between 1 to 5 from little fat deposition to large fat 
deposition on the face, ribs and buttocks. This study found a positive correlation 
between the fetal nutrition score and the modified neonatal nutritional score. To date, 
3D evaluation of the fetal buttocks has not been replicated in recent literature.  
A promising 3D ultrasound marker is fractional thigh volume.124 In the last part of 
pregnancy, the thigh fat volume is highly associated with neonatal percentage fat 
mass.125-126 As fetal fat accumulation starts from the late second trimester until 
delivery, the late trimester may be more predictive of fetal fat accretion as it increases 
exponentially in the third trimester, may be most informative in late pregnancy.127 A 
study by Roelants et al128 measured 3D fetal thigh volume  at 22, 26 and 32 weeks of 
gestation. Neonatal percentage body fat was measured few days postnatally.  Routine 
fetal biometry assessment done prior to 3D acquisition of the fetal thigh. 3D volumes 
of the fetal thigh were obtained in the routine femur length measurement on a 
longitudinal view. This study showed that the 3D fetal thigh volume correlates well 
with neonatal fat accretion from mid-gestation onward.  
The ongoing search for different fetal parameters that can be measured in utero will 
hopefully flourish as ultrasound is an accessible non-invasive tool that is easily 
available in all institution.  
2.7.6.2. Magnetic resonance imaging 
MRI has been used in the recent years for fetal fat measurement. But due to its limited 
availability and training of clinicians, its use in pregnancy is very specific and limited 
to evaluation of fetal anomalies like brain migrational disorders. It can discriminate 
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among tissue components that cannot be distinguished on ultrasound. MRI is also 
indicated in conditions where things do not favor fetal ultrasound such as cases of 
maternal obesity or anhydramnios. 
MRI can be used for evaluation of the fetal subcutaneous fat thickness on certain fetal 
compartments, as with ultrasound, this assessment may not be representative of the 
whole fetal fat body distribution. Anblagan et al129 evaluated the reliability of magnetic 
resonance imaging in measuring fetal fat volume in utero. T1-weighted MRI with fat 
suppression can discriminate between the fat layer and water. The study found that 
there was a significant positive correlation between BW percentile and fetal fat 
volume, percentage fetal fat and calculated fetal weight at 34 weeks gestation. MRI is 
therefore potentially of value in the evaluation abnormal fat accretion and disturbed 
fetal growth in the third trimester. The technique demonstrates maternal and fetal fat 
composition on different sites. (Figure 2-23)   
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Figure 2-23. MRI (T1-weighted) image of maternal and fetal fat volumes (Red 
arrow - maternal subcutaneous fat, Green arrow - fetal subcutaneous fat 
surrounding abdomen and legs, Yellow arrow - fetal intra-abdominal fat)129 
Since 2013 with work of Anblagan et al, the interest in fetal MRI fat evaluation has 
increased. In 2018, Blondiaux et al studied retrospectively the developmental pattern 
of fetal fat signal on T1-weighted sequences during the second and third trimesters.130 
This group found that between 26 weeks and 33 weeks of gestation, subcutaneous fetal 
fat signal changed in an orderly pattern from chin to buttocks and scalp. This may 
reflect the conversion from brown to white adipose tissues. There was a gradual and 
consistent change in intensity per gestation. Adipose tissue function changes with 
development.  
 
	 62	
2.8. Neonatal body composition measurements 
2.8.1. Anthropometric measurements 
Skinfold thickness measurements on multiple sites are typically used to assess body 
composition. It is easy to perform, cheap and non-invasive. Although they are often 
less reliable especially in obese patients.131  
Sumners et al132 performed neonatal anthropometry within few days of birth and 
utilized standard methods. The results showed that skinfold determination may provide 
a good estimate of fetal energy store. The group measured the crown heel length and 
skinfold thickness at different sites and summed up all together.  
2.8.2. Blood tests 
Lemas et al133 pioneered the Healthy Start study. This is a large observational cohort 
study of 753 pregnant women determining the neonatal metabolic profile and whole-
body air-displacement plethysmography as a measure of neonatal adiposity. Maternal 
BMI and weight gain was also determined. This study found that increased maternal 
weight prior and during pregnancy is associated with increased neonatal leptin, glucose 
and HDL at delivery. These findings suggest that intrauterine exposure to maternal 
obesity influences offspring cardiovascular and metabolic profile. 
2.8.3. Magnetic resonance imaging 
Rasmussen et al134 validated the first the methods for quantitative brown adipose tissue 
(BAT) MRI imaging on rodents and then analysed on infants. This study demonstrates 
the reliability of MRI in quantifying BAT in human neonates. 
2.8.4. Dual energy X-ray absorptiometry, bioimpedance and densitometry 
There are various methods in evaluation of neonatal body composition. BW135 and 
skinfold thickness136 are employed commonly however these methods poorly correlate 
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with body fat percentage and composition. MRI, dual energy X-ray absorptiometry, 
BIA are limited due to their limited availability.  
The MiG TOFU trial (Metformin in gestational diabetes: the offspring follow-up)133 
followed up the body composition of the offspring of women enrolled in the MiG trial 
(Metformin vs insulin for the treatment of gestational diabetes)138 at 7 years in 
Adelaide and and 9 years in Auckland. Body fat percentage measured by imaging 
studies including MRI, dual energy X-ray absorptiometry and bioimpedance. Routine 
anthropometric assessments also done including fasting blood tests. Results showed 
that the difference between total and body fat percentage and cardiometabolic profile 
between the two groups was not significant. Although the metformin group tend to 
have larger offspring in terms of upper long bones circumference and skinfold 
thickness. Overall, these data are reassuring for clinicians using metformin in women 
with GDM. 
Roelants et al128 as previously mentioned, assessed the association between fetal 3D 
fractional thigh volume from 22 weeks until delivery and neonatal percentage fat mass. 
The group have also used air-displacement plethysmography to measure total 
percentage fat of the neonate. This prospective perinatal study showed that fetal thigh 
volume from the mid-semester of pregnancy correlates well with neonatal fat 
accretion. This will provide early strategies in monitoring offspring at risk of future 
obesity and other related diseases.  
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3.  Determination of fetal fat distribution in pregnancy and its correlation with 
maternal subcutaneous fat and body mass index 
3.1. Abstract  
3.1.1. Objectives: 
The aim of this study is to investigate the association between maternal visceral obesity 
and fetal abdominal and peripheral fat distribution in different trimesters for different 
BW quartiles.  
3.1.2. Methods:  
This is a retrospective analysis of 1363 women at a tertiary perinatal ultrasound centre 
from 2012-2014.  Maternal subcutaneous fat thickness (SFT) and BMI were used to 
correlate with fetal fat measures in the second and third trimester. The maternal 
abdominal SFT measurement has been used as a surrogate for central obesity. 
Neonates were divided into BW quartiles for statistical analysis. Fetal fat thickness 
was measured by the first author blinded against clinical data. 
3.1.3. Results:  
Outcome data were available for 845 and 674 women in the second and third trimesters 
respectively.  Maternal SFT was positively correlated with fetal abdominal 
subcutaneous fat in Q2 babies (p=0.01) and with negative correlation with fetal 
peripheral fat on the lowest BW quartile babies Q1 (p=0.04). Multivariate analysis 
showed that maternal SFT is a positive predictor of fetal abdominal subcutaneous fat 
for Q4 babies in the second trimester (p=0.04).  
3.2.4. Conclusion:  
Maternal adiposity can predict fetal fat distribution in the second trimester of 
pregnancy. The observed trend in the correlation of fetal fat distribution with maternal 
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measures of adiposity was weak. Further prospective research may determine whether 
these correlations are reproducible and stronger.  
3.2. Introduction 
The obesity epidemic manifests also in the pregnant population, with 40-50% of 
Australian pregnant women defined as overweight or obese.12 This has significant 
effects on maternal wellbeing with obesity correlated with gestational diabetes, 
hypertensive disorders of pregnancy and increased risk of obstetric intervention.10,11 In 
addition, the offspring of these women are more likely to have adverse neonatal 
complications including birth defects, hypoglycaemia, lower Apgar scores, premature 
delivery, admission to neonatal intensive care unit and macrosomia.12,13  Furthermore, 
these offspring are more susceptible to childhood and adulthood obesity, along with 
its associated sequelae including metabolic and cardiovascular disease states.13-18 
Indeed, there is growing consensus that intrauterine environment influences fetal 
growth and development with lifelong effects, although the mechanisms remain to be 
elucidated.18-19, 139 The obesogenic environment in pregnancy has been postulated to 
be one of the influences of aberrant fetal growth and programming.18,22,119,139-141 
Obesity and overweight has traditionally been defined by BMI.  However, recent 
research has uncovered a more sensitive relationship between the distribution of 
maternal body fat and offspring’s short and longterm outcomes.139 Central adiposity 
(defined as fat in the thoraco-abdominal area) is more metabolically active than 
peripheral adiposity (fat in the thighs and bottom), with central adiposity linked with 
more adverse outcomes.18,144,146 Similarly, in pregnancy, this effect is replicated.10-12,23 
Measurement of maternal abdominal subcutaneous fat can be considered a surrogate 
marker for central adiposity.12,23   
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Fetal size is routinely assessed by ultrasound fetal biometry, with abnormal fetal 
growth detected by deviations from established growth trajectories.115 There is little 
data surrounding the impact of maternal central adiposity as measured by abdominal 
SFT on fetal fat distribution. The aim of this study was to explore the effect of BMI 
and maternal central adiposity on fetal fat during the second and third trimester.  
 3.3. Materials and Methods 
This is a retrospective analysis of clinical and ultrasound data collected at a tertiary 
perinatal ultrasound between 2012 and 2014. Participants were originally enrolled in a 
cohort study that assessed maternal abdominal subcutaneous fat thickness (SFT) 
measured by ultrasound in the first and second trimester of pregnancy as an 
independent predictor of adverse pregnancy outcomes.12 As we have no pilot data, we 
are unable to provide power calculations. Expected dataset was approximately 50% of 
the original cohort study population which should be enough to test the hypothesis. 
Maternal demographic data was collected at the initial entry. This includes age, 
ethnicity, parity, smoking and history of pre-existing disease like hypertension and 
diabetes. Majority of women included were from White population (94%) with only 
2.9% Asian background, 2.1% Aboriginal and 0.3% African. Women who develop 
preeclampsia and gestational diabetes during the pregnancy were also collected. 
Booking BMI calculated using BMI calculator for women.  
Data for the present study was collected from images stored on the Viewpoint 6 (GE 
Healthcare) fetal databases at the Nepean Centre for Perinatal Care, Perinatal 
Ultrasound Nepean Hospital and Penrith Ultrasound for Women. Ultrasound was 
performed on each participant in the second trimester for morphology scan and/or third 
trimester growth scan. Those included in the study had a singleton pregnancy with 
EDD confirmed at the 11-14 weeks, low risk combined first trimester screening and 
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normal 18-22 weeks ultrasound examination. Participants with an abnormality found 
in the fetus, multiple pregnancies and insulin dependent diabetes mellitus were 
excluded. 
The dependent variables include fetal thigh and abdominal fat which were measured 
in the second and third trimester. The fetal abdominal fat was measured on a routine 
abdominal circumference measurement. The circumference of the inner border of the 
echogenic fetal fat measured and then subtracted from the abdominal circumference 
measurement (Figure 3-1). The fetal subcutaneous thigh fat was measured from the 
average of the two distal ends and the mid-shaft of the fetal femur length on a 
longitudinal view. The average of the three vertical measurements recorded (Figure 3-
2). The rate of fetal abdominal and peripheral fat accumulation was also calculated by 
subtracting the fetal fat thickness measured in the second and third trimester then 
divided by the number of days in between ultrasound measurements. Ultrasound 
measurements were performed offline by the first author blinded against all clinical 
data. Degree of agreement of measures between two operators was assessed using 
intraclass correlation (ICC).  Second set of measurements were performed repeatedly 
by a qualified sonographer. 
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Figure 3-1. Fetal abdominal subcutaneous measurement on transverse view 
 
 
Figure 3-2. Fetal thigh subcutaneous measurement on longitudinal view 
 
 
	 69	
Maternal abdominal adiposity was assessed during routine ultrasound examination. As 
described before,23 this was measured in the middle of abdominal wall superior to the 
symphysis pubis through the linea alba. Three measurements taken, one in the middle 
and two measurements lateral to it with 5mm distance then averaged to obtain the mean 
subcutaneous thickness of the abdominal wall. Calipers were placed on the echogenic 
subcutaneous fat. (Figure 3-2).  
The study was conducted in the context of a parent project that had been approved by 
the local institutional Human Research Ethics Committee (reference Study 11/54 – 
HREC/11/Nepean/91).  
Statistical analysis was undertaken using SPSS version 21 (SPSS Inc., Chicago, IL, 
USA). Fetal fat measures were analysed based on neonatal BW which were divided 
into quartiles. Neonates were grouped into four equal sized sets based on their 
statistical ranking. Data was assessed for normal distribution using Kolmogorov-
Smirnov and Shapiro-Wilk. Pearson’s correlation was used for normally distributed 
parameters otherwise Spearman’s rho correlation was used for non-normal 
distribution. Correlation was performed to determine the strength of relationship 
between fetal fat with maternal subcutaneous fat and BMI. R values closer to +1 or -1 
indicates strong linear relationship between the two variables. Multiple regression 
analysis with stepwise elimination analysis was used to adjust for maternal and fetal 
covariates. A high b coefficient signifies strong effect on the dependent variable. A 
significance level of p £ 0.05 was used for all analyses.  
 
 
 
 
	 70	
3.4. Results 
Outcome data available for 845 women in the second trimester and 674 women in the 
third trimesters from a total 1363 women from the original cohort study. Only 62% of 
women included in the original study had ultrasound in the second trimester in our 
unit. Third trimester scans were not indicated in some women in the study. This will 
account for the reduced number of patients that were measured in the third trimester. 
The maternal and fetal ultrasound measurements were summarised on Table 3.1 and 
Table 3.2. 
Table 3.1 Mean maternal variable 
 
 
Table 3.2. Mean fetal fat variables 
Fetal outcome 
variables 
Second trimester 
Mean (mm) ± SD 
Third trimester 
Mean (mm) ± SD 
AC 6.96 ± 0.98 14.21 ± 2.52 
FL 0.66 ± 0.13 3.23 ± 1.01 
 
All neonates were then stratified into BW quartiles. BW mean and range of the 
neonates in each quartile were summarised on Table 3.3. Correlation analysis showed 
maternal SFT was negatively correlated with fetal thigh fat accumulation in the second 
trimester in the lowest quartile (Q1) (r=-0.14, p=0.04). There was a positive trend for 
abdominal and peripheral adiposity for Q2, Q3 and Q4. This positive trend was 
significant in Q2 only in the second trimester with r=0.18, p=0.01 respectively for both 
maternal SFT and BMI (Table 3.4). Consistency of measurements between two 
operators showed an intraclass correlation coefficient was 0.88. 
 
 
Maternal variables Mean (mm) ±SD 
Maternal subcutaneous fat 20.29 ± 7.69 
BMI 26.99 ± 6.26 
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Table 3.3. Neonatal BW quartiles (in grams) 
 Mean BW BW range 
Quartile 1 2716.08 ± 489.61 2835 - 3160 
Quartile 2 3327.37 ± 80.28 3164 - 3450 
Quartile 3 3612.47 ± 93.50 3455 -3775 
Quartile 4 4098.24 ±274.32 3780 - 5355 
 
Table 3.4. Spearman’s rho correlation analysis of maternal BMI and SFT with 
fetal adiposity 
Fetal fat variables  
(second & third 
trimester) 
      
 
 Q1 
BMI 
 
Q2 
 
 
Q3 
 
 
   Q4 
      
 
 Q1 
SFT 
 
Q2 
 
 
Q3 
 
 
   Q4 
FL second             R 
                  p value 
-0.09       
 0.19 
0.02         
 0.79 
0.67       
0.35 
0.08*      
0.25 
-0.14       
0.04 
0.07         
0.36 
0.04      
0.57 
0.12*     
0.08 
AC second            R 
                  p value 
-0.01        
0.85 
0.18          
0.01 
0.04      
 0.54 
0.10        
0.13 
-0.03       
0.66 
0.18         
0.01 
0.02      
0.82 
0.05       
0.45 
FL third                R 
                  p value 
 0.10         
0.16 
0.08          
0.33 
0.05       
0.54 
0.01*      
0.93 
0.03        
0.13 
0.05         
0.55 
0.04      
0.62 
0.04*     
0.60 
AC third               R 
                  p value 
-0.01*      
0.92 
0.03*        
0.74      
0.11*     
0.15 
0.07*     
 0.37 
0.05*      
0.51 
0.05*       
0.49 
0.02*    
0.80 
0.01*     
0.96    
  *Pearson’s correlation 
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Multiple regression analysis was undertaken to assess the ability of other maternal and 
fetal variables to predict fetal fat thickness from the second trimester. This analysis 
showed that the rate of fetal abdominal and peripheral fat accumulation is a significant 
predictor of fetal adiposity in most quartiles from the second to third trimester and fetal 
gender is a significant positive predictor only in the highest quartile (Q4) and Q2 group 
in the second and third trimester respectively.  Smoking (p=0.03), preeclampsia 
(p=0.01), nulliparity (p=0.05) and parity ³2 (p=0.01) are significant predictors of fetal 
fat thickness in the second trimester while age (p=0.05) was significant only in the third 
trimester.  Maternal SFT is a positive predictor of fetal abdominal fat for Q4 babies in 
the second trimester (β=0.23, p=0.04) with average weight of about 4.1 kg. This was 
also observed in the Q2 babies by using stepwise elimination analysis in the third 
trimester both for fetal abdominal (β=0.05, p=0.004) and peripheral adiposity (β=0.02, 
p=0.01). Women with normal BMI tend to have lesser fetal fat distribution on Q3 
babies. This finding was significant only in the third trimester.  
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Table 3.5. Multiple regression analysis of fetal fat variables in the second trimester  
 
Maternal & fetal parameters 
Q1 
AC 
 
FL 
Q2 
AC 
 
FL 
Q3 
AC 
 
FL 
Q4 
AC 
 
FL 
Essential hypertension             β 
                                      p value                  
0.04 
0.85
0.02 
0.57 
-0.12 
0.62 
0.06 
0.10 
0.15 
0.60 
0.03 
0.56 
0.33 
0.34 
0.001 
0.96 
Preeclampsia                             β 
                                      p value 
-0.15 
0.64 
0.01 
0.83 
0.48 
0.19 
-0.15 
0.01 
0.48 
0.59 
-0.12 
0.46 
-0.46 
0.44 
0.001 
0.96 
GDM                                        β 
                                      p value 
-0.30 
0.22 
0.00 
0.96 
-0.05 
0.81 
0.001 
0.90 
-0.08 
0.82 
0.09 
0.16 
-0.05 
0.88 
0.04 
0.43 
Insulin requiring GDM            β 
                                      p value 
-0.18 
0.57 
-0.01 
0.86 
0.16 
0.63 
-0.06 
0.28 
-0.26 
0.57 
0.14 
0.07 
-1.42 
0.15 
0.21 
0.12 
Age                                           β 
                                      p value  
-0.02 
0.16 
0.00 
0.30 
-0.02 
0.25 
0.001 
0.68 
0.01 
0.62 
0.001 
0.34 
0.001 
0.90 
0.001 
0.08 
Smoking                                   β 
                                      p value 
0.00 
0.98 
-0.01 
0.63 
-0.10 
0.63 
0.06 
0.07 
0.10 
0.61 
-0.08 
0.03 
-0.66 
0.04 
0.04 
0.41 
Parity – 0                                  β 
                                      p value  
-0.37 
0.10 
-0.04 
0.21 
-0.48 
0.05 
-0.05 
0.17 
0.16 
0.49 
0.07 
0.08 
0.41 
0.22 
0.05 
0.29 
Parity – 1                                  β 
                                      p value 
-0.16 
0.49 
-0.04 
0.18 
-0.44 
0.08 
0.06 
0.14 
0.11 
0.65 
0.07 
0.11 
0.47 
0.16 
0.05 
0.29 
Parity ≥2                                   β 
                                      p value 
-0.28 
0.25 
-0.01 
0.71 
-0.01 
0.96 
0.12 
0.01 
0.18 
0.48 
0.05 
0.24 
0.25 
0.47 
0.04 
0.41 
SFT                                           β 
                                      p value 
0.001 
0.85 
0.001 
0.78 
0.01 
0.30 
0.03 
0.41 
0.001 
0.73 
0.001 
0.73 
0.23 
0.04 
0.001 
0.16 
BMI ≤25                                   β 
                                      p value 
-0.03 
0.89 
-0.01 
0.77 
-0.09 
0.64 
0.001 
0.32 
-0.16 
0.41 
-0.05 
0.15 
0.20 
0.39 
0.02 
0.47 
	 74	
BMI ≥25.01                              β 
                                      p value 
-0.02 
0.94 
-0.02 
0.44 
0.21 
0.24 
0.03 
0.30 
0.30 
0.27 
0.07 
0.08 
0.21 
0.29 
0.02 
0.55 
Fetal gender                              β 
                                      p value 
0.07 
0.59 
0.001 
0.90 
0.001 
0.98 
0.02 
0.24 
0.09 
0.48 
0.04 
0.09 
0.42 
0.001 
0.05 
0.01 
Rate of AC                               β 
                                      p value 
   3.51 
0.001 
0.14 
0.08 
2.93 
0.001 
0.09 
0.23 
3.49 
0.001 
0.13 
0.20 
2.67 
0.001 
0.21 
0.01 
Rate of FL                                β 
                                      p value 
3.31 
0.02 
0.05 
0.83 
1.15 
0.38 
0.02 
0.93 
3.13 
0.02 
0.85 
0.001 
1.48 
0.28 
0.12 
0.52 
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Table 3.6. Multiple regression analysis of fetal fat variables in the third trimester 
 
Maternal & fetal parameters 
Q1 
AC 
 
FL 
Q2 
AC 
 
FL 
Q3 
AC 
 
FL 
Q4 
AC 
 
FL 
Essential hypertension             β 
                                      p value                  
0.57 
0.29 
0.19 
0.28 
0.46 
0.43 
0.25 
0.19 
0.70 
0.31 
0.22 
0.29 
0.12 
0.88 
-0.04 
0.89 
Preeclampsia                             β 
                                      p value 
0.42 
0.56 
0.07 
0.77 
-0.21 
0.81 
-0.28 
0.31 
-0.95 
0.65 
-0.72 
0.27 
-1.72 
0.20 
-0.39 
0.40 
GDM                                        β 
                                      p value 
-0.08 
0.89 
0.16 
0.36 
-0.33 
0.52 
-0.17 
0.29 
0.10 
0.91 
0.20 
0.46 
-0.71 
0.36 
-0.23 
0.39 
Insulin requiring GDM            β 
                                      p value 
0.25 
0.72 
0.25 
0.27 
-0.13 
0.88 
0.27 
0.31 
-0.47 
0.67 
-0.01 
0.98 
-0.60 
0.79 
0.07 
0.93 
Age                                           β 
                                      p value  
0.02 
0.53 
0.01 
0.24 
-0.04 
0.23 
-0.01 
0.49 
0.02 
0.58 
0.01 
0.43 
0.04 
0.19 
0.02 
0.05 
Smoking                                   β 
                                      p value 
0.20 
0.58 
0.01 
0.92 
0.23 
0.63 
0.04 
0.82 
0.34 
0.49 
0.12 
0.43 
-0.59 
0.45 
-0.08 
0.75 
Parity – 0                                  β 
                                      p value  
-0.53 
0.29 
-0.06 
0.73 
-0.31 
0.57 
0.15 
0.38 
0.62 
0.26 
0.13 
0.43 
0.75 
0.30 
0.10 
0.68 
Parity – 1                                  β 
                                      p value 
0.32 
0.52 
-0.06 
0.70 
-0.14 
0.79 
0.21 
0.25 
0.78 
0.16 
0.26 
0.13 
1.24 
0.09 
0.21 
0.40 
Parity ≥2                                   β 
                                      p value 
-0.19 
0.73 
0.10 
0.57 
0.53 
0.34 
0.37 
0.07 
0.33 
0.59 
0.05 
0.78 
1.22 
0.11 
0.30 
0.24 
SFT                                           β 
                                      p value 
0.02 
0.49 
0.00 
0.80 
0.04 
0.09 
0.01 
0.12 
-0.02 
0.40 
-0.01 
0.27 
0.03 
0.38 
0.01 
0.49 
BMI ≤25                                   β 
                                      p value 
-0.18 
0.69 
-0.17 
0.24 
-0.20 
0.65 
-0.06 
0.70 
-1.13 
0.02 
-0.42 
0.001 
0.67 
0.22 
0.26 
0.16 
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BMI ≥25.01                              β 
                                      p value 
0.29 
0.48 
-0.02 
0.87 
0.20 
0.62 
-0.03 
0.81 
-0.61 
0.16 
-0.23 
0.08 
0.66 
0.16 
0.22 
0.18 
Fetal gender                              β 
                                      p value 
0.16 
0.57 
0.05 
0.56 
0.64 
0.03 
0.29 
0.001 
0.21 
0.49 
0.07 
0.50 
0.50 
0.12 
0.13 
0.26 
Rate of AC                               β 
                                      p value 
6.20 
0.001 
0.82 
0.03 
10.34 
0.001 
0.17 
0.66 
13.15 
0.001 
1.12 
0.01 
11.33 
0.001 
0.14 
0.78 
Rate of FL                                β 
                                      p value 
7.83 
0.02 
14.28 
0.001 
2.62 
0.93 
13.10 
0.001 
5.27 
0.11 
14.15 
0.001 
2.63 
0.41 
14.27 
0.001 
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3.5. Discussion 
Maternal obesity plays an important role in affecting aberrant fetal growth. Maternal 
factors that affect the intrauterine growth environment and exert their effects as 
phenotypic alterations may include maternal nutrition, placental transport capacity and 
maternal body composition.12, 22, 141 It has been demonstrated that maternal SFT is a 
predictor for adverse pregnancy outcomes.12 Traditionally, BMI has been used as a 
marker of overnutrition but it does not take into account the distribution or proportion 
of fat.12 Whilst maternal BMI has been consistently shown to be correlated  with 
neonatal adiposity and macrosomia, the effect of maternal BMI on fetal growth 
remains controversial due to conflicting findings.13,22,142  
The present study demonstrated a significant correlation in the second trimester 
between maternal SFT and fetal abdominal and peripheral adiposity in the lowest two 
quartiles. Abdominal adiposity in the fetus was also significantly correlated with BMI. 
Correlation analysis showed as well a positive trend on fetal adiposity measurements 
on the upper three quartiles although the correlation was weak. The findings were only 
significant in the second trimester which is similar with the results of the study by 
Roelants et al128 wherein successive evaluation of fetal thigh volume between 22 and 
32 weeks of gestation showed minimal benefit for prediction of neonatal adiposity 
when compared with a single fractional thigh 3D volume measurement at 
midgestation.  
An observational study by Lopes et al, of 592 women also demonstrated a significant 
correlation between maternal SFT and all measures of fetal biometry during the second 
trimester only.  However, no relationship between BMI and any measures of fetal 
biometry were found. Maternal visceral subcutaneous fat in pregnancy is associated 
with increased neonatal adiposity and BW and is more likely to predict increased BW 
	 78	
than BMI.22 This was also supported in our study, stratifying the neonates into 
quartiles, abdominal adiposity in highest quartile babies is better predicted by maternal 
SFT than BMI. Other studies have also demonstrated maternal visceral fat alters the 
neuroendocrine milieu and may impact fetal growth patterns. A prospective study of 
92 women in the second trimester demonstrated a positive correlation between 
maternal abdominal SFT and maternal inflammatory markers and HBA1C.143 This 
maternal metabolic state may affect fetal growth and programming.144  
Abdominal circumference is the most sensitive of all fetal growth measures to detect 
fetal overgrowth and is most strongly correlated with neonatal body fat percentage.17,14 
It is also the measure deemed most reliable to perform in pregnant obese women.146   
The importance of the AC measurement may be of great significance in understanding 
the mechanisms behind aberrant fetal programming in the obesogenic environment. 
The liver is the dominant organ in the AC measurement and has been implicated as a 
key organ in determining abnormal fetal growth trajectories through liver proliferation, 
altered gluconeogenic enzymes and increased hepatic fat deposition.141-142 The AC also 
incorporates measures of fetal visceral adiposity, with subcutaneous and 
intraabdominal fat accumulation, which may remain postnatally and become 
metabolically active visceral fat.  
In support of this hypothesis that the liver is central to alterations in fetal growth and 
programming, a prospective study of 62 pregnant women demonstrated fetal liver 
blood flow during early third trimester was linked to newborn body fat percentage and 
total fat mass.147 Animal studies have demonstrated in sheep that excessive caloric 
intake led to increased fetal liver size and weight, compared to recommended caloric 
intake controls,  and it was postulated that greater lipid content of livers accounted for 
this.142  In addition, high fat diets have resulted in increased hepatic lipid content in 
	 79	
rats and animal primates.142 In diabetic pregnancies, fetal AC measurements have been 
used to guide insulin therapy during second trimester, with a resultant decrease in 
macrosomia.149 A prospective cohort study involving 125 pregnant women 
demonstrated a positive correlation between anterior abdominal wall thickness and AC 
in the third trimester and resultant BW.144 The interplay between the liver and visceral 
fat and its effect on fetal growth and programming is poorly understood and requires 
further investigation.  
There are several methods available for assessing the fetal fat regions, particularly for 
the abdomen and extremities. Comparative analysis of different of techniques at this 
present time has not been undertaken. There is growing interest in evaluation of fetal 
fat to better predict growth disturbance in fetus and to formulate in utero strategies to 
prevent continued rise in the incidence of obesity and monitor at risk offspring. The 
common sites that were assessed for fetal fat are the extremities and the abdominal 
circumference. Numerous studies were able to predict macrosomic fetuses by 
measuring the fetal abdominal fat thickness110-111 and discriminate a growth restricted 
fetus from a fetus low risk for perinatal morbidity and mortality by measuring fetal 
thigh fat thickness and volume. 112, 128   
These fetal compartments contains fat stores, but which one predominates is not yet 
known. As mentioned in previous discussion in fetal fat development, the critical 
period of fat tissue development occurs in the second trimester where there is full 
differentiation and deposition of the entire fetal body with fat tissues. Whether fat 
deposition in this critical period is the same in all population or differences exists 
between different maternal demographics like ethnicity and BMI. There are several 
maternal factors that can influence fetal growth and distribution of fetal fat like age, 
ethnic background, BMI, gestational weight gain, hypertension and diabetes. Whether 
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or not assessment of fetal fat will provide additional information on fetal fat 
distribution has not been explored in obese patients.  
Our study has certain limitations. It is a retrospective study with mainly White 
population.  The first author measured the inner border of the fetal fat AC and 
remeasured the outer border of fetal AC only if not correctly measured.  This might 
have affected the ICC calculated coefficient. The assessment of fetal fat thickness was 
obtained from a routine AC and FL measurements which were quick with good 
reproducibility. The first author was blinded to avoid any form of bias. BMI was 
measured and not self-reported. This is in contrast to Lopes who acknowledged self-
reporting of pre-pregnancy BMI as a limitation of their study, as it usually leads to 
under reporting of weight. However, despite us weighing the participants there was 
still no correlation evident between BMI and any measure of fetal fat distribution.  
3.6. Conclusion 
In conclusion, this study illustrated that fetal peripheral fat is less on the lowest quartile 
babies but trending positively on overall fetal adiposity on the upper quartile babies. 
In addition, it was observed that fetal abdominal adiposity was better predicted with 
maternal SFT on the highest quartile neonates with mean BW of over 4 kg than BMI.  
Both of these observations however were significant only in the second trimester and 
the size effect is small. Further research is needed to see if this is of clinical value. 
The current study measured fetal fat thickness of the thigh and abdomen. As there is 
no standardised technique in assessing this fetal parameters, we have used a different 
method of measurement. Whether or not our technique had influenced the results needs 
to be elucidated further. 
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